Sanjay Mathew
Vice Chair for Research at Baylor College of Medicine
Data updated
Research Footprint
Sanjay Mathew appears in 26 tracked papers (2012–2024), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: James Murrough, Daniel Iosifescu and Dennis Charney.
Background & Research
Dr. Sanjay Mathew directs the Mood and Anxiety Disorders Program at Baylor College of Medicine. His research program is dedicated to discovering novel pharmacotherapies for difficult-to-treat depression and PTSD, with a primary focus on the rapid-acting effects of ketamine. He has significantly contributed to the literature on the pathophysiology of anxiety and the clinical management of treatment-resistant patients.
Key Impact
Leading expert in experimental therapeutics for treatment-resistant mood and anxiety disorders.
Collaboration Network
35 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Sanjay Mathew is associated with.
Baylor College of Medicine
Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.
View stakeholder →Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.
View stakeholder →Mount Sinai
hospitalThe Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.
View stakeholder →